N/A N=22 Diagnosing Intensive Care Unit (ICU) Acquired Weakness
ICU Acquired Weakness
Primary: Peak Acceleration Measured in Extensor Carpi Radialis Longus — 0.476; 1.639; 0.541; 1.608 units of Gravity
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=201 A Study in Older Participants Who Have Fallen and Have Muscle Weakness
Muscle Weakness
Primary: Change From Baseline to 24 Week Endpoint in Appendicular Lean Body Mass (aLBM) — 0.303; -0.123 kilograms (kg) — p=<0.001
Phase 4 N=10 Examining the Effect of Burosumab on Muscle Function
X-linked Hypophosphatemia
Primary: Skeletal Muscle Adenosine Triphosphate (ATP) Synthesis Rate — 9.41 umol/g/min — p=0.4147
N/A N=22 Testing of a New Therapeutic Vibration Device to Reduce Neuromuscular Weakness in Hospitalized Patients
Critically Ill · Post Intensive Care Syndrome
Primary: Change in Regional Hemoglobin Oxygen Saturation — 75.65; 77.01; 73.83; 77.09 percent of oxygenation — p=<0.0001
N/A N=27 Muscle Weakness and Post-traumatic Knee OA
Meniscectomy
Primary: Change in International Knee Documentation Committee (IKDC) Subjective Knee Form Score — 22.2; 20.6 units on a scale
N/A N=23 Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
Knee Osteoarthristis
Primary: Cross-sectional Area (CSA) of Muscle Fibers — 2680; 2377; 2028; 1882 micron squared
Phase 2 N=56 Power Training Post-stroke
Stroke
Primary: Gait Speed — 0.51 meters per second
N/A N=34 Use of Neuromuscular Electrostimulation (NMES) for Treatment or Prevention of ICU-Associated Weakness
Intensive Care Unit · Muscle Weakness
Primary: Lower Extremity Strength, at Hospital Discharge, of 3 Bilateral Muscle Groups (Pretibial, Triceps Surae, and Quadriceps) Measured Via MMT Using a Composite Medical…
Phase 1 N=19 Electrical Stimulation for Critically Ill Covid-19 Patients
Covid19 · Muscle Atrophy · Muscle Weakness
Primary: Change in Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 352; 323 milliVolts
N/A N=86 Comparison of Repetitive Magnetic Stimulation and Exercise on Quadriceps Function in COPD
Chronic Obstructive Pulmonary Disease
Primary: Quadriceps Fibre Size of Type IIa Fibres — 3885; 4326; 3610 micrometers squared
Phase 2 N=19 Electrical Stimulation for Critically Ill Post-Covid-19 Patients
COVID-19 · Muscle Atrophy · Muscle Weakness
Primary: Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 363.04; 359.55 miliVolts
Early Phase 1 N=32 Premature Fatigue in Veterans With Heart Failure: Neuronal Influences
Heart Failure
Primary: Maximal Voluntary Quadriceps Force [% Change From Baseline] — -30; -5 percentage change
Phase 2 N=37 A Study of Muscle Strength Maintenance in Older Adults
Sarcopenia
Primary: Change From Baseline in Isokinetic Strength — -4.90; -4.73 Newton — p=0.97
N/A N=20 Preventing the Loss of Muscle and Function in Hospitalized Older Adults
Muscular Atrophy
Primary: The Percent Change in Bilateral Thigh Lean Mass Density (Grams) as Measured by DEXA Scan Will be Compared Between Baseline and After 5-days of Bed Rest — -3.845; -0.249…
Phase 4 N=11 Using Clonidine to Improve Leg Weakness in People With Heart Failure
Heart Failure
Primary: Change in Citrate Synthase Activity as an Estimate of Mitochondrial Activity — -0.3; 0.07 micromole/min/wet weight
N/A N=30 Muscle Fatigue and Scapular Sensorimotor System
Muscle; Fatigue
Primary: Change From Baseline in Scapular Proprioception — -0.48; -0.19; -0.37; -0.32 centimeters — p=0.227
N/A N=8 7 Tesla MRI Study in Patients With Statin Related Muscle Complaints
Statin-related Muscle Pain · Muscle Aches · Muscle Weakness
Primary: Change in Pre- and Post-phosphocreatine Relaxation Time — 5.58; 5.083 milliseconds
N/A N=73 Effect of EPA and HMB on Strength in ICU Patients
Muscle Weakness
Primary: Change of Skeletal Muscle Strength for One of the Drugs Compared to Placebo — 1.3; 0.1; 1.5; 0.7 cm H2O
N/A N=120 Treatment of Critical Illness Polyneuromyopathy
Acute Respiratory Failure
Primary: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 — 19.0; 20.9…
N/A N=12 Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability
Fatigue · Aging
Primary: Change in Muscle Fatigue After 1 Week of Placebo or Sildenafil — 107; 115; 54; 158 percent change of successful repetitions — p=0.02
Phase 3 N=42 Expiratory Muscle Training for Persons With Neurodegenerative Disease
Parkinson's Disease · Multiple Sclerosis
Primary: Maximum Expiratory Pressure (MEP) — 78.6; 75.56; 99.00; 99.38 cm H2O — p=0.899
Phase 2 N=32 Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Lambert-Eaton Myasthenic Syndrome · Eaton-Lambert Myasthenic Syndrome
Primary: Number of Participants With 30% or More Deterioration in Triple Timed Up & Go (3TUG) Test, Compared to Time-matched Baseline — 0; 13 Participants — p=<0.0001
N/A N=30 Predictors of the Ability to Protect the Airway in Long-term Ventilated Patients
Swallowing Disorder · Aspiration · Long Term Ventilation
Primary: Muscle Strength — 20; 10 participants
N/A N=44 Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults
Sarcopenia · Aging · Immune Function
Primary: Change in Plasma Concentration of Antibodies to Pertussis Antigen (1 Week Post-vaccine) — 63.1; 63.2 units per ml — p=>0.05
Phase 2 N=63 Antioxidant Therapy in RYR1-Related Congenital Myopathy
Neuromuscular Disease
Primary: Urine 15-F2t Isoprostane Concentration — 2.7; 2.6 ng/mg Cr — p=0.88
N/A N=37 Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients
Chronic Kidney Disease
Primary: Maximal Oxygen Uptake — 14.5; 15.1 ml/kg/min
Phase 2 N=120 Metformin and Muscle in Insulin-resistant Older Veterans
Prediabetes
Primary: Change in Total Lean Mass From Baseline — 322.8; 697.6; 392.4; 548.0 grams lean mass — p=0.45
Phase 2 N=20 Weekly Steroids in Muscular Dystrophy
Limb-girdle Muscular Dystrophy · Becker Muscular Dystrophy
Primary: Fasting Glucose — 93; 102 mg/dL
N/A N=34 Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients
Parkinson's Disease · Multiple Sclerosis
Primary: Blood Lactate Response — 1.7; 1.6; 1.2; 2.3 mmol/L
Phase 4 N=19 Fade Upon TOF Stimulation Induced by Succinylcholine
Muscle Relaxants
Primary: Fade on Train of Four Stimulation — 0.85; 0.64; 0.66; 0.68 Ratio